Andreas Krause

List of Publications by Year
in descending order

56 papers	2,135 citations	331670 21 h-index	233421 45 g-index
58 all docs	58 docs citations	58 times ranked	3185 citing authors

#	Article	IF	Citations
1	Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects. Clinical Pharmacokinetics, 2022, 61, 687-695.	3.5	2
2	Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel. Clinical and Translational Science, 2022, 15, 1906-1915.	3.1	3
3	Estimation of Attainment of Steady‐State Conditions for Compounds With a Long Half‐Life. Journal of Clinical Pharmacology, 2021, 61, 82-89.	2.0	5
4	PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 213-224.	1.8	5
5	Pharmacokinetic/pharmacodynamic modeling of drug interactions at the $P2Y_{12}$ receptor between selatogrel and oral $P2Y_{12}$ antagonists. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 735-747.	2.5	7
6	The Case for an Unblinded Modeler in Early Clinical Development. Journal of Clinical Pharmacology, 2020, 60, 369-377.	2.0	0
7	Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists. Pharmaceutical Research, 2020, 37, 2.	3.5	6
8	Modelling pharmacokinetics and pharmacodynamics of the selective $S1P_1$ receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients. British Journal of Clinical Pharmacology, 2020, 86, 791-800.	2.4	4
9	Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development. Scientific Reports, 2020, 10, 4410.	3.3	10
10	Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development*. Pharmaceutical Statistics* 17 (5):593–606, Sep/Oct 2018, DOI: 10.1002/pst.1873. Pharmaceutical Statistics, 2019, 18, 278-281.	1.3	1
11	Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2018, 49, 140-146.	2.6	5
12	Confidence and Prediction Intervals for Pharmacometric Models. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 360-373.	2.5	26
13	Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis. Journal of Dermatological Science, 2018, 89, 136-145.	1.9	11
14	Modeling Tolerance Development for the Effect on Heart Rate of the Selective $S1P_1$ Receptor Modulator Ponesimod. Clinical Pharmacology and Therapeutics, 2018, 103, 1083-1092.	4.7	15
15	Pediatric Development of Bosentan Facilitated by Modeling and Simulation. Paediatric Drugs, 2017, 19, 121-130.	3.1	2
16	Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes. Pharmaceutical Research, 2017, 34, 599-609.	3.5	11
17	Target-Mediated Drug Disposition Pharmacokinetic–Pharmacodynamic Model of Bosentan and Endothelin-1. Clinical Pharmacokinetics, 2017, 56, 1499-1511.	3.5	10
18	Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast. Journal of Clinical Pharmacology, 2017, 57, 1042-1052.	2.0	5

#	Article	IF	Citations
19	Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development. European Journal of Pharmaceutical Sciences, 2017, 109, S53-S58.	4.0	8
20	Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 477-485.	2.5	7
21	Mitigation of Initial Cardiodynamic Effects of the S1P$_1$ Receptor Modulator Ponesimod Using a Novel Up‐Titration Regimen. Journal of Clinical Pharmacology, 2017, 57, 401-410.	2.0	16
22	Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949. British Journal of Clinical Pharmacology, 2017, 83, 476-486.	2.4	48
23	Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies. Clinical Pharmacokinetics, 2017, 56, 395-408.	3.5	9
24	Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects. British Journal of Clinical Pharmacology, 2016, 82, 412-421.	2.4	28
25	Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects. European Journal of Pharmaceutical Sciences, 2016, 89, 83-93.	4.0	3
26	Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. British Journal of Clinical Pharmacology, 2016, 82, 369-379.	2.4	25
27	Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection. Clinical Pharmacokinetics, 2016, 55, 813-821.	3.5	7
28	Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P$_1$ receptor modulator: Favorable impact of dose up-titration. Journal of Clinical Pharmacology, 2014, 54, 179-188.	2.0	60
29	Tolerability and Pharmacokinetics of ACT-280778, a Novel Nondihydropyridine Dual L/T-type Calcium Channel Blocker. Journal of Cardiovascular Pharmacology, 2014, 63, 120-131.	1.9	4
30	A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial. Clinical Drug Investigation, 2014, 34, 807-818.	2.2	31
31	Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage. European Journal of Clinical Pharmacology, 2014, 70, 409-419.	1.9	5
32	Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 261-278.	1.8	22
33	Visualization and Communication of Pharmacometric Models With Berkeley Madonna. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-20.	2.5	33
34	Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. British Journal of Clinical Pharmacology, 2012, 74, 978-989.	2.4	9
35	Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics, 2010, 2, 364-388.	4.5	75
36	Interactive Visualization and Communication for Increased Impact of Pharmacometrics. Journal of Clinical Pharmacology, 2010, 50, 140S-145S.	2.0	4

#	Article	IF	Citations
37	Visualization Concepts to Enhance Quantitative Decision Making in Drug Development. Journal of Clinical Pharmacology, 2010, 50, 130S-139S.	2.0	4
38	Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole. Journal of Clinical Oncology, 2009, 27, 1382-1387.	1.6	93
39	Predicting response and resistance to endocrine therapy. Cancer, 2008, 112, 689-694.	4.1	25
40	Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenetics and Genomics, 2007, 17, 813-826.	1.5	94
41	Modeling and Simulation to Adjust p Values in Presence of a Regression to the Mean Effect. American Statistician, 2007, 61, 302-307.	1.6	8
42	Aromatase inhibitorsâ€"Gene discovery. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 130-142.	2.5	24
43	Estrogen-Independent Proliferation Is Present in Estrogen-Receptor $HER2$-Positive Primary Breast Cancer After Neoadjuvant Letrozole. Journal of Clinical Oncology, 2006, 24, 3019-3025.	1.6	170
44	A standard curve based method for relative real time PCR data processing. BMC Bioinformatics, 2005, 6, 62.	2.6	780
45	Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience. Endocrine-Related Cancer, 2005, 12, S119-S123.	3.1	6
46	Efficacy of Rivastigmine in Alzheimerâ€™s Disease Patients with Rapid Disease Progression: Results of a Meta-Analysis. Dementia and Geriatric Cognitive Disorders, 2005, 20, 192-197.	1.5	46
47	Aromatase inhibitors: Cellular and molecular effects. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 83-89.	2.5	21
48	The validation of new aromatase monoclonal antibodies for immunohistochemistryâ€"A correlation with biochemical activities in 46 cases of breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 35-39.	2.5	62
49	Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood, 2004, 103, 2929-2935.	1.4	57
50	An integrated view of aromatase and its inhibition. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 413-421.	2.5	32
51	Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation, 2003, 75, 1323-1330.	1.0	96
52	Optimized Protocol for Linear RNA Amplification and Application to Gene Expression Profiling of Human Renal Biopsies. BioTechniques, 2003, 34, 546-556.	1.8	43
53	Electronic services in statistics. Computational Statistics and Data Analysis, 1995, 19, 595-604.	1.2	3
54	The hierarchical Tobit model: A case study in Bayesian computing. OR Spectrum, 1994, 16, 145-154.	3.4	5

#	ARTICLE	IF	CITATIONS
55	Modeling of Discontinuous Relationships in Biology with Censored Regression. American Naturalist, 1994, 143, 494-507.	2.1	36
56	Bayesian Regression Model with Simple Errors in Variables Structure. Journal of the Royal Statistical Society: Series D (the Statistician), 1993, 42, 571.	0.2	8